VERS.L Regulatory News (VERS)

4 February 2016

Verseon Corporation

("Verseon" or the "Company")

Additional Listing & Total Voting Rights

Verseon, a technology-based pharmaceutical company, announces that on 29 January 2016, Restricted Stock Units ("RSUs") previously granted to Dr. Thomas Hecht, Non-Executive Chairman of the Company, representing 4,322 Common Shares, vested and shall be issued following the publication of the Company's results for the 12 months ending 31 December 2015. A further announcement shall be made in due course as and when such are issued and application is made to AIM for admission to trading. The RSUs relate to payment of his Director's fees in the form of restricted stock as has been previously disclosed in announcements made on 25 September 2015 and 29 October 2015. Dr. Hecht's restricted stock grant totalling 17,291 Common Shares was made on 10 September 2015 and calculated by reference to the closing price on 10 September 2015 of the Company's common shares in USD, being $3.47. The RSUs vest quarterly in equal proportions over a one year period starting from 29 April 2015.

Issue of Common Shares

Separately, the Company announces that application has been made for 416,166 new Common Shares of par value $0.001 each (the "Common Shares") to be admitted to trading on AIM pursuant to the exercise of options and warrants (the "Exercise"). The 416,166 new Common Shares issued pursuant to the Exercise will rank pari passu with the Company's existing Common Shares and admission to trading on AIM is expected to take place on 9 February 2016 ("Admission").

 Total Voting Rights

Following Admission, the issued share capital of the Company will consist of 151,354,981 Common Shares. The Company does not hold any shares in treasury. Therefore the total number of Common Shares in the Company with voting rights will be 151,354,981. This figure may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change in their interest in, the share capital of the Company under the FCA's Disclosure and Transparency Rules.

-Ends-

For further information please contact: